CHAPTER

Folate, Folic Acid, and Folinic Acid

Biochemistry, Clinical Pharmacology, and Integrative Applications

A Comprehensive Review for Clinicians, Researchers, and Students

Prepared for Academic Publication

Abstract

Vitamin B9 exists in three distinct forms that are frequently, and incorrectly, treated as interchangeable. Folate refers to the naturally occurring reduced tetrahydrofolate derivatives found in food; folic acid is the fully oxidized synthetic form used in fortification and most supplements; and folinic acid (5-formyltetrahydrofolate, leucovorin) is a reduced derivative that enters one-carbon metabolism downstream of dihydrofolate reductase. These differences determine which patients respond to which form of vitamin B9 supplementation.

This chapter provides a comprehensive review of folate biochemistry and its translation into clinical practice. It traces the one-carbon cycle from intestinal absorption and transport through the dihydrofolate reductase bottleneck, the methylenetetrahydrofolate reductase (MTHFR) node, the methionine cycle, and the nucleotide synthesis arm, identifying precisely where each folate form enters. It examines the pharmacokinetics of all three forms and reviews the evidence and open questions surrounding unmetabolized folic acid. A pharmacogenomics section covers MTHFR C677T and A1298C alongside variants in DHFR, MTR, MTRR, FOLR1, SLC19A1, SLC46A1, TYMS, and CBS, with attention to the distinction between a susceptibility factor and a diagnosis.

The chapter surveys clinical applications across neural tube defect prevention, cardiovascular disease, oncology (including methotrexate rescue and 5-fluorouracil modulation), cerebral folate deficiency, depression, obstetric outcomes, chronic kidney disease, and autoimmune disease. Integrative considerations address form selection, cofactor dependencies, drug-nutrient interactions, and laboratory assessment, and the chapter closes with a stepwise clinical decision framework.

Throughout, claims are calibrated to the strength of the underlying evidence. Where mechanistic reasoning outpaces outcome data — as with methylfolate for neural tube defect prevention, the significance of unmetabolized folic acid, and the construct of over-methylation — this is stated explicitly rather than obscured. The intent is to equip clinicians to individualize folate therapy on defensible grounds and to articulate the reasoning behind that choice.

Keywords: folate; folic acid; folinic acid; leucovorin; 5-methyltetrahydrofolate; MTHFR; one-carbon metabolism; methylation; unmetabolized folic acid; cerebral folate deficiency; neural tube defects; pharmacogenomics; integrative medicine

Table of Contents

1. Introduction and Historical Context

Few nutrients have undergone as dramatic a journey from obscurity to public health mandate as vitamin B⁹. The story begins in 1931, when Lucy Wills observed that a yeast extract (later identified as containing folate) could reverse megaloblastic anemia in pregnant textile workers in Bombay.¹ That observation launched nearly a century of research that has linked folate status to everything from embryonic neural tube closure to cardiovascular risk stratification, cognitive aging, and cancer surveillance.

The term folate derives from the Latin folium (leaf), reflecting its abundance in dark leafy greens. By the 1940s, the compound had been isolated from spinach and characterized as pteroylglutamic acid — the fully oxidized form we now call folic acid.² The distinction between natural food folates and synthetic folic acid would prove clinically consequential, but that recognition came decades later, driven by pharmacogenomic insights into methylenetetrahydrofolate reductase (MTHFR) polymorphisms and the discovery of unmetabolized folic acid (UMFA) in fortified populations.

A third player — folinic acid (5-formyltetrahydrofolate, leucovorin) — entered clinical practice through oncology, where its capacity to bypass dihydrofolate reductase (DHFR) inhibition made it an essential rescue agent during high-dose methotrexate therapy.³ More recently, folinic acid has found applications in neuropsychiatry, cerebral folate deficiency syndromes, and integrative protocols for autism spectrum disorder, extending its relevance far beyond the chemotherapy suite.

This chapter provides a comprehensive, evidence-based review of all three forms. We trace the biochemistry from pteridine ring structure through one-carbon metabolism, examine the pharmacokinetics and pharmacogenomics that determine clinical response, survey the major disease-state applications, and close with practical guidance for both conventional and integrative practice settings.

2. Chemistry and Molecular Structure

2.1 The Pteridine Core

All folate species share a common backbone: a pteridine ring linked via a methylene bridge to para-aminobenzoic acid (PABA), which is in turn conjugated to one or more glutamate residues. The pteridine ring is the catalytically active portion — its nitrogen atoms at positions 5 and 10 serve as the docking sites for the one-carbon units (methyl, methylene, methenyl, formyl, and formimino groups) that drive nucleotide synthesis, amino acid metabolism, and epigenetic methylation.⁴

2.2 Folic Acid: The Fully Oxidized Synthetic Form

Folic acid (pteroylmonoglutamic acid) is the fully oxidized form of the vitamin. It does not occur in significant quantities in nature. Its stability and bioavailability — approximately 85% when consumed on an empty stomach, compared to roughly 50% for food folates — made it the form of choice for food fortification programs and pharmaceutical supplements.⁵ However, this oxidized state also means folic acid is biologically inert until the body reduces it, a process that is rate-limited and genetically variable.

2.3 Tetrahydrofolate and Natural Folates

Food folates exist predominantly as polyglutamylated, reduced tetrahydrofolate (THF) derivatives. Before absorption, intestinal γ-glutamyl hydrolase (conjugase) cleaves them to monoglutamate forms. The principal circulating form in human plasma is 5-methyltetrahydrofolate (5-MTHF), which accounts for more than 90% of serum folate under normal physiological conditions.⁶ This is a critical point: the body's own preferred currency is 5-MTHF, not folic acid.

2.4 Folinic Acid: The Reduced, DHFR-Independent Form

Folinic acid (5-formyltetrahydrofolate; leucovorin) is a reduced folate derivative that enters the folate pool downstream of the DHFR-catalyzed reduction step. Because it does not require DHFR for activation, it remains functional even when DHFR is pharmacologically inhibited (as in methotrexate therapy) or genetically compromised.⁷ Clinically, folinic acid is available as both the racemic (d,l-leucovorin) and the biologically active levo-isomer (levoleucovorin), the latter offering improved bioavailability at half the dose.

3. One-Carbon Metabolism: The Folate Cycle in Detail

3.1 Absorption and Transport

Folate absorption occurs primarily in the proximal jejunum via the proton-coupled folate transporter (PCFT/SLC46A1). At the brush border, polyglutamylated food folates are deconjugated by glutamate carboxypeptidase II (GCPII).⁸ Once absorbed as monoglutamates, folates circulate bound to serum proteins — predominantly albumin, with a smaller fraction bound to folate-binding proteins (FBPs). Cellular uptake involves the reduced folate carrier (RFC/SLC19A1) for most tissues, while the folate receptors (FRα and FRβ) mediate receptor-mediated endocytosis, particularly in the choroid plexus (critical for CNS folate delivery), kidneys, and placenta.⁹

3.2 The DHFR Bottleneck

Folic acid must undergo two sequential reductions by dihydrofolate reductase (DHFR): first to dihydrofolate (DHF), then to tetrahydrofolate (THF). Human DHFR has notably low activity compared to other species — estimates suggest human hepatic DHFR operates at roughly 2% of the capacity seen in rat liver.¹⁰ This rate limitation is the biochemical basis for the accumulation of unmetabolized folic acid (UMFA) in serum when intake exceeds the DHFR processing threshold, typically estimated at around 200–400 μg in a single oral bolus.

3.3 The MTHFR Node

Once THF is formed, it can acquire one-carbon units in various oxidation states. The enzyme 5,10-methylenetetrahydrofolate reductase (MTHFR) catalyzes the irreversible NADPH-dependent conversion of 5,10-methylene-THF to 5-MTHF, committing the one-carbon unit to the methylation pathway. The C677T polymorphism (Ala222Val) reduces MTHFR thermostability and enzymatic activity to approximately 30% (homozygous TT) or 65% (heterozygous CT) of wild-type levels.¹¹ The A1298C variant has a milder effect individually but compounds with C677T. Together, these polymorphisms affect an estimated 40–60% of many populations worldwide, making MTHFR one of the most commonly clinically discussed pharmacogenomic targets in integrative medicine.

3.4 The Methionine Cycle and Methylation

5-MTHF donates its methyl group to homocysteine via the vitamin B¹²-dependent enzyme methionine synthase (MTR), regenerating methionine and producing THF. Methionine is then activated by methionine adenosyltransferase (MAT) to form S-adenosylmethionine (SAMe), the universal methyl donor for over 200 methyltransferase reactions — including DNA methylation (via DNMTs), histone methylation, neurotransmitter synthesis, phospholipid methylation (PEMT), and creatine synthesis.¹²

After donating its methyl group, SAMe becomes S-adenosylhomocysteine (SAH), which is hydrolyzed back to homocysteine, completing the cycle. This tight coupling between the folate cycle and the methionine cycle means that impaired folate metabolism reverberates through the entire methylation machinery — with downstream consequences for epigenetic regulation, neurotransmitter balance, and detoxification capacity.

3.5 The Nucleotide Synthesis Arm

Folate-derived one-carbon units are also essential for de novo purine synthesis (via 10-formyl-THF, contributing carbons 2 and 8 of the purine ring) and thymidylate synthesis (via 5,10-methylene-THF and thymidylate synthase). When folate is insufficient, uracil is misincorporated into DNA in place of thymine — a source of chromosomal fragility and a proposed mechanism linking folate deficiency to both megaloblastic anemia (impaired erythropoiesis from DNA synthesis failure) and carcinogenesis.¹³

3.6 Where Folinic Acid Enters the Cycle

Folinic acid (5-formyl-THF) is converted by 5,10-methenyltetrahydrofolate synthetase (MTHFS) to 5,10-methenyl-THF, which then feeds into both the methylation and nucleotide synthesis arms of the cycle. Critically, this entry point is entirely downstream of DHFR, which is why folinic acid rescues cells from methotrexate toxicity — it replenishes the THF pool that methotrexate has depleted by inhibiting DHFR.¹⁴ This same property makes folinic acid attractive in clinical scenarios where DHFR function is compromised genetically, pharmacologically, or nutritionally.

4. Pharmacokinetics and Bioavailability

4.1 Folic Acid Pharmacokinetics

Folic acid demonstrates near-complete absorption (~85–95%) in the fasting state when consumed as a supplement, and approximately 85% when added to food. Peak serum concentrations occur within 1–2 hours of oral ingestion. However, the conversion to metabolically active forms depends on DHFR capacity. At doses above approximately 200 μg, unmetabolized folic acid begins to appear in the systemic circulation and may persist for hours.¹⁵ The half-life of folic acid elimination is complex and dose-dependent, but functional body stores are estimated at 10–30 mg, with a half-life of total body folate depletion of approximately 100 days on a folate-free diet.

4.2 5-MTHF (Methylfolate) Pharmacokinetics

5-MTHF (as calcium or glucosamine salt, e.g., Metafolin®, Quatrefolic®) demonstrates bioavailability at least equivalent to folic acid at equimolar doses. In a crossover study, Willems et al. compared 5 mg oral doses of folic acid and racemic 6[R,S]-5-methyltetrahydrofolate in patients with coronary artery disease and found that 5-MTHF produced substantially greater bioavailability, with peak plasma folate concentrations roughly sevenfold higher than folic acid.¹⁶ A separate and important pharmacological argument for 5-MTHF is that, unlike folic acid, it does not generate unmetabolized folic acid (UMFA) in the circulation, since it enters the folate pool downstream of the DHFR reduction step that produces UMFA when folic acid intake is high.^15,17

4.3 Folinic Acid Pharmacokinetics

When administered orally, folinic acid is well absorbed with peak concentrations at 1–2 hours. The racemic form (d,l-leucovorin) contains 50% biologically active l-isomer; levoleucovorin offers equivalent rescue at half the dose. Intravenous folinic acid achieves immediate tissue distribution and is preferred for methotrexate rescue protocols where time to active folate is critical. Priest et al. characterized the pharmacokinetics of leucovorin metabolites in human plasma and demonstrated dose-dependent increases in 5-MTHF as the principal circulating metabolite.^7,18

4.4 Unmetabolized Folic Acid (UMFA): The Emerging Concern

Since the institution of mandatory folic acid fortification in 1998 (United States and Canada), detectable levels of UMFA have been documented in a significant proportion of the population, including pregnant women and neonates.¹⁷ The clinical significance of circulating UMFA remains actively debated. Proposed concerns include:

• Competitive inhibition at folate receptors and the reduced folate carrier, potentially impeding cellular uptake of bioactive folates.
• Immune modulation — some observational data suggest associations between high folic acid intake and altered natural killer cell cytotoxicity, though causal evidence is lacking.
• Masking of vitamin B¹² deficiency by correcting the hematological manifestations (megaloblastic anemia) while allowing neurological damage to progress undetected.
• Potential epigenetic effects through altered methyl donor availability, with theoretical implications for tumorigenesis — although the epidemiological data here is conflicting and remains inconclusive.¹⁹

It bears emphasis that UMFA remains a mechanistic concern with incomplete clinical evidence. Public health authorities, including the WHO and U.S. Preventive Services Task Force, continue to endorse folic acid fortification on the basis of the robust neural tube defect (NTD) prevention data. Nevertheless, the question has significant implications for clinical practice, particularly in integrative and functional medicine settings where patients may be consuming folic acid from multiple fortified foods and supplements simultaneously.

5. Pharmacogenomics of Folate Metabolism

5.1 MTHFR Polymorphisms

The two most studied variants — C677T (rs1801133) and A1298C (rs1801131) — affect enzyme activity, thermostability, and FAD (riboflavin) binding. The C677T TT genotype is associated with elevated homocysteine (particularly when folate status is low), altered global DNA methylation, and increased risk for NTDs, cardiovascular events, and certain cancers in some populations. Prevalence varies significantly by ethnicity: TT homozygosity ranges from approximately 10–12% in European and East Asian populations to 25–32% in some Mexican and Italian populations.²⁰

Clinical relevance is modulated by folate status — adequate folate intake can largely normalize homocysteine and methylation even in TT carriers. This underscores that MTHFR genotype is a susceptibility factor, not a deterministic diagnosis, and its clinical significance is context-dependent. Long and Goldblatt have cautioned against routine MTHFR testing in asymptomatic individuals, noting that the common C677T and A1298C variants are poor predictors of clinical disease in isolation and that testing can generate unnecessary anxiety and unvalidated interventions.²¹ Their concern is appropriate — treating the genotype as a stand-alone disease entity is reductionist. Separately, however, the pharmacogenomic rationale for selecting the bioactive folate form (5-MTHF) in patients with documented MTHFR variants and demonstrated functional impairment (e.g., persistently elevated homocysteine, inadequate response to folic acid) retains clinical logic, even if it extends beyond what routine genotyping guidelines endorse.

5.2 Other Relevant Polymorphisms

Beyond MTHFR, several other genetic variants influence folate metabolism and response to supplementation:

• DHFR polymorphisms (19-bp deletion in intron 1): Associated with reduced folic acid metabolism and higher UMFA levels in some studies. May amplify the case for non-folic acid folate forms in carriers.²²
• MTR (A2756G) and MTRR (A66G): Affect methionine synthase and its reductase, influencing the B¹²-dependent remethylation of homocysteine. Compound heterozygosity with MTHFR variants may synergistically impair methylation.
• FOLR1 (folate receptor alpha): Mutations in FOLR1 cause cerebral folate transport deficiency — a treatable neurodegenerative disorder in which folate delivery across the choroid plexus is impaired despite normal systemic folate levels. Steinfeld et al. characterized this as a distinct entity associated with disturbed myelin metabolism.²³ Separately, polymorphisms in FOLR1 and FOLR2 have been variably implicated in neural tube defects and some autism spectrum presentations, though the evidence base is less robust than for MTHFR.
• SLC19A1/RFC (G80A): Affects reduced folate carrier function, potentially altering cellular folate uptake and methotrexate pharmacokinetics.
• SLC46A1/PCFT: Mutations cause hereditary folate malabsorption — a distinct entity from the FOLR1-related cerebral folate transport deficiency — characterized by systemic and CNS folate depletion from impaired intestinal absorption.
• TYMS (thymidylate synthase): 28-bp tandem repeat polymorphisms affect enzyme expression, modifying both cancer risk and response to 5-fluorouracil-based chemotherapy.
• CBS (cystathionine beta-synthase): Influences the transsulfuration pathway, affecting the balance between homocysteine remethylation and its conversion to cysteine and glutathione. Particularly relevant in patients with concurrent sulfur metabolism concerns.²⁴

6. Clinical Applications: Disease States and Therapeutic Strategies

6.1 Neural Tube Defect Prevention

The prevention of neural tube defects (NTDs) — anencephaly, spina bifida, and encephalocele — stands as the most impactful public health application of folate supplementation. Landmark trials, including the MRC Vitamin Study (1991), demonstrated a 72% reduction in NTD recurrence with periconceptional folic acid supplementation at 4 mg/day.²⁵ This evidence led to the 1998 U.S. mandate for folic acid fortification of enriched grain products (140 μg/100 g), which has been credited with a 25–30% decline in NTD prevalence.

The question of whether 5-MTHF might be equally or more effective for NTD prevention remains open. Mechanistically, 5-MTHF bypasses the MTHFR and DHFR bottlenecks and avoids UMFA accumulation. Prinz-Langenohl et al. demonstrated in a pharmacokinetic study that oral 5-MTHF raised plasma folate more effectively than equimolar folic acid in women homozygous for the C677T polymorphism, providing a rationale for preferential use in this population.²⁶ Some clinician groups have adopted 5-MTHF for prenatal supplementation in women with known MTHFR variants or prior NTD-affected pregnancies. However, large-scale population outcome data directly comparing 5-MTHF to folic acid for NTD prevention are not yet available, creating a tension between pharmacokinetic and mechanistic rationale on one hand and robust epidemiological evidence on the other.

6.2 Cardiovascular Disease and Homocysteine

Elevated plasma homocysteine has been associated with increased risk for atherosclerotic cardiovascular disease, stroke, and venous thromboembolism. Folate (along with vitamins B⁶ and B¹²) effectively lowers homocysteine levels. However, large randomized trials (HOPE-2, VITATOPS, NORVIT, SEARCH) have yielded mixed results on whether homocysteine lowering translates to reduced cardiovascular events.²⁷

A Cochrane meta-analysis by Martí-Carvajal et al. concluded that homocysteine-lowering B-vitamin supplementation did not significantly reduce myocardial infarction or all-cause mortality, though a modest reduction in stroke risk was observed.²⁷ Separately, the CSPPT trial (Huo et al., 2015) demonstrated that combined enalapril-folic acid therapy reduced first stroke by 21% compared to enalapril alone in Chinese adults with hypertension and no prior stroke or MI — a population without mandatory folate fortification.²⁸ Current consensus holds that homocysteine is more likely a modifiable risk marker than a primary causal driver of cardiovascular disease, though it remains a useful clinical indicator of methylation adequacy and B-vitamin status.

6.3 Oncology: Prevention, Treatment, and the Dual Role of Folate

Folate's relationship with cancer is paradoxical and has been described as a 'double-edged sword.' Adequate folate status appears protective against colorectal, breast, and other cancers — likely through maintenance of DNA integrity and proper methylation. However, once neoplastic foci are established, excess folate may promote tumor growth by fueling nucleotide synthesis in rapidly dividing cells.²⁹

Key oncology applications include:

• Methotrexate rescue with folinic acid: High-dose methotrexate (HDMTX) protocols in osteosarcoma, lymphoma, and leukemia rely on timed leucovorin rescue to protect normal tissues from DHFR blockade. Dosing and timing are protocol-specific but universally critical: rescue is initiated at a defined interval after the MTX infusion and continued until serum MTX clears below a target threshold, commonly in the range of 0.05–0.1 μmol/L depending on the regimen.³⁰
• 5-Fluorouracil (5-FU) modulation: Folinic acid enhances the cytotoxicity of 5-FU against colorectal cancer by stabilizing the ternary complex of 5-FU metabolite (FdUMP), thymidylate synthase, and 5,10-methylene-THF. The FOLFOX and FOLFIRI regimens include leucovorin as a standard component.³¹
• Pemetrexed (Alimta®) pretreatment: Folic acid (not folinic acid) supplementation is required to reduce the myelosuppressive and mucosal toxicities of this multi-targeted antifolate used in mesothelioma and non-small cell lung cancer.
• Folate status in cancer survivorship: Post-treatment folate optimization is an increasingly discussed element of integrative oncology survivorship care, balancing the need for adequate methylation support against the theoretical concern of promoting residual disease.

6.4 Neuropsychiatry and Cerebral Folate Deficiency

Cerebral folate deficiency (CFD) is a syndrome characterized by low 5-MTHF in the cerebrospinal fluid despite normal peripheral folate levels. Originally described in children with neurodevelopmental regression, it has since been recognized in a broader range of presentations including treatment-resistant depression, schizophrenia, and autism spectrum disorder. Ramaekers and Blau provided an early clinical characterization of CFD,³² and subsequent work by Ramaekers et al. (2005) identified serum autoantibodies against folate receptor alpha (FRα) as a key pathophysiological mechanism, demonstrating their presence in the majority of CFD patients and showing clinical improvement with folinic acid therapy.³³

In CFD, folinic acid (leucovorin) is the treatment of choice over folic acid because:

• Folinic acid can cross the blood-brain barrier via the reduced folate carrier, bypassing FRα receptor blockade.
• Folic acid may paradoxically worsen CFD by competitively occupying the residual functional FRα receptors without delivering active folate to the CNS.
• 5-MTHF is sometimes used as an alternative or adjunct; some clinicians prefer it for milder presentations or in combination protocols.

The randomized, double-blind, placebo-controlled trial by Frye et al. (2018) demonstrated that high-dose folinic acid (2 mg/kg/day, maximum 50 mg/day) improved verbal communication in children with autism spectrum disorder and language impairment, particularly in those with positive FRα autoantibodies.³⁴ This represents one of the more rigorously evidence-supported interventions in the integrative management of autism.

6.5 Depression and Methylation-Based Interventions

Folate deficiency has been consistently associated with increased risk of depression and poorer response to antidepressant therapy. The mechanism likely involves impaired SAMe production, which is required for the synthesis of serotonin, dopamine, and norepinephrine (via cofactor supply for tryptophan hydroxylase and tyrosine hydroxylase).³⁵

L-methylfolate (as Deplin®, 7.5–15 mg) is marketed as a medical food — a category regulated under the Orphan Drug Act and 21 CFR 101.9 — for the clinical dietary management of suboptimal folate levels in depressive disorders.³⁶ It is not FDA-approved as a drug, and the medical food designation has been a subject of regulatory discussion. Clinical trial data from Papakostas et al. (2012) showed adjunctive l-methylfolate at 15 mg/day significantly improved response rates in SSRI-resistant major depressive disorder.³⁷

Clinicians should be attentive to potential symptoms sometimes described as 'overmethylation' (anxiety, irritability, insomnia) in some patients receiving high-dose methylfolate. It is important to state plainly that this is a clinical construct reported anecdotally rather than a formally defined biochemical state validated in controlled trials; no published study has directly demonstrated methylfolate-induced overmethylation or established that COMT genotype predicts susceptibility to it. What is well established is that the COMT gene harbors a common functional polymorphism (Val158Met) that substantially alters enzyme activity and catecholamine turnover,³⁸ which provides a plausible — but as yet unproven — mechanistic rationale for why methylation-modifying interventions might produce variable neuropsychiatric responses. Pending direct evidence, conservative dose titration starting at lower amounts (e.g., 1–2.5 mg) remains a reasonable clinical precaution in sensitive patients.

6.6 Pregnancy Beyond NTDs: Broader Obstetric Outcomes

Folate status influences a spectrum of pregnancy outcomes beyond neural tube defects, though the evidence for each outcome differs in strength and should not be pooled uncritically. A population study with systematic review and meta-analysis by Hodgetts et al. found that folic acid supplementation in pregnancy was associated with a reduced risk of small-for-gestational-age neonates.³⁹ For hypertensive disorders, a meta-analysis by Liu et al. found that folic acid supplementation significantly reduced the risk of preeclampsia — an effect driven mainly by multivitamin preparations containing folic acid rather than folic acid alone — while finding no association with gestational hypertension.⁴⁰ For cardiac malformations, van Beynum et al. reported a modest protective association between periconceptional folic acid use and congenital heart defects (odds ratio 0.82; 95% CI 0.68–0.98) in a registry-based case–control study.⁴¹ Periconceptional folic acid supplementation has also been linked, in a large prospective cohort by Surén et al., to a reduced risk of autism spectrum disorder in offspring.⁴² These are observational associations; none establishes causality, and they remain areas of active investigation rather than settled conclusions.

The placenta expresses high levels of FRα, and placental folate transport is an area of active research. Gestational diabetes, preeclampsia, and placental insufficiency may all impair folate transport, creating a functional deficiency even when serum levels appear adequate. This has led some clinicians to favor higher-dose 5-MTHF supplementation during pregnancy, particularly in high-risk pregnancies, though standardized dosing guidelines for this approach have not yet been established.

6.7 Chronic Kidney Disease and Dialysis

Patients with chronic kidney disease (CKD) frequently develop hyperhomocysteinemia due to impaired renal clearance of homocysteine and altered folate metabolism. While folate supplementation lowers homocysteine in CKD populations, the HOST trial and other studies have not demonstrated clear cardiovascular benefit from homocysteine lowering in dialysis patients.⁴³ Nonetheless, folate repletion remains standard practice for managing anemia and supporting erythropoiesis in conjunction with erythropoiesis-stimulating agents.

6.8 Autoimmune and Inflammatory Conditions

Low-dose methotrexate (7.5–25 mg/week) is a cornerstone of treatment for rheumatoid arthritis, psoriasis, and other autoimmune conditions. Concurrent folic acid supplementation (typically 1–5 mg daily, excluding the day of methotrexate) reduces the gastrointestinal, hepatic, and hematologic side effects of methotrexate without significantly diminishing its therapeutic efficacy.⁴⁴ Folinic acid can be used in patients who do not tolerate folic acid or who experience breakthrough toxicity, though some evidence suggests folinic acid may reduce methotrexate efficacy more than folic acid in this low-dose anti-inflammatory context — an important distinction from its role in high-dose oncologic rescue.

7. Integrative and Functional Medicine Considerations

7.1 Choosing the Right Form

The question of which folate form to prescribe is one of the most frequently encountered decisions in integrative practice. A framework for clinical decision-making includes:

• Folic acid: Remains appropriate for population-level fortification and for patients without known polymorphisms, UMFA concerns, or neuropsychiatric presentations. Cost-effective and backed by the largest evidence base for NTD prevention.
• 5-MTHF (methylfolate): Preferred for patients with known MTHFR polymorphisms (especially C677T TT), elevated homocysteine, UMFA concerns, depression augmentation, and prenatal supplementation in high-risk pregnancies. Avoids the DHFR bottleneck and UMFA accumulation.
• Folinic acid (leucovorin): Indicated for methotrexate rescue, cerebral folate deficiency, autism spectrum protocols (particularly with positive FRα autoantibodies), and neuropsychiatric conditions where CNS folate delivery is a concern. Preferred over folic acid in CFD because it bypasses both DHFR and FRα blockade concerns.

7.2 Cofactor Considerations

Folate does not operate in isolation. Optimal one-carbon metabolism requires concurrent adequacy of:

• Vitamin B¹² (methylcobalamin or hydroxocobalamin): Essential cofactor for methionine synthase. B¹² deficiency can cause a 'methyl trap' where 5-MTHF accumulates but cannot donate its methyl group, functionally depleting other folate forms despite adequate total folate.
• Vitamin B⁶ (pyridoxal-5'-phosphate): Required for the transsulfuration pathway (CBS) and multiple aminotransferases.
• Riboflavin (B²): FAD is a cofactor for MTHFR. Riboflavin supplementation has been shown to lower homocysteine independently in MTHFR 677TT carriers and is an underappreciated intervention.⁴⁵
• Betaine (trimethylglycine): Provides an alternative remethylation pathway via betaine-homocysteine methyltransferase (BHMT), primarily in the liver and kidney.
• Choline: Intersects with folate metabolism via the betaine pathway. Choline demand increases during pregnancy; inadequate choline may exacerbate the consequences of folate insufficiency.
• Zinc, magnesium, and iron: Support various enzymes in one-carbon metabolism and erythropoiesis.

7.3 Drug-Nutrient Interactions

Multiple commonly prescribed medications interfere with folate metabolism:

• Methotrexate: Direct DHFR inhibition (discussed extensively above).
• Trimethoprim and pyrimethamine: DHFR inhibitors used as antimicrobials. Prolonged use can deplete folate stores.
• Anticonvulsants (phenytoin, carbamazepine, valproate, phenobarbital): Impair folate absorption, increase folate catabolism, and may interfere with folate-dependent enzymes.
• Sulfasalazine: Inhibits PCFT-mediated folate absorption.
• Oral contraceptives: May modestly reduce serum folate levels, though the clinical significance is debated.
• Proton pump inhibitors and H² blockers: Chronic use may impair folate absorption by increasing gastric pH, though evidence is inconsistent.
• Metformin: Associated with reduced serum folate and B¹² levels through unclear mechanisms.

7.4 Laboratory Assessment

A comprehensive folate assessment in integrative practice may include:

• Serum folate: Reflects recent intake; a single low value may not indicate true tissue depletion.
• RBC folate: Better indicator of long-term folate status (reflects stores over the preceding 120-day RBC lifespan).
• Plasma homocysteine: Functional marker of folate, B¹², and B⁶ adequacy.
• Methylmalonic acid (MMA): Helps distinguish B¹² deficiency from folate deficiency (elevated in B¹² deficiency only).
• UMFA levels: Available through specialty labs; useful for assessing folic acid overexposure, though not yet widely standardized.
• MTHFR genotyping: Widely available; useful for guiding form selection but should be interpreted in clinical context, not as a standalone diagnosis.
• FRα autoantibodies: Indicated in suspected cerebral folate deficiency, autism evaluations, and treatment-resistant neuropsychiatric presentations. Available through specialty laboratories (e.g., ILIAD Neurosciences).

8. Safety, Toxicology, and Upper Limits

Folate is a water-soluble vitamin with a generally excellent safety profile. The U.S. Institute of Medicine (1998) established a tolerable upper intake level (UL) for folic acid at 1,000 μg/day for adults, based primarily on the concern for masking B¹² deficiency.⁴⁶ This UL was set specifically for synthetic folic acid; the 1998 IOM report did not establish a separate UL for food folate or for 5-MTHF supplementation.

However, regulatory positions have since evolved. The European Food Safety Authority (EFSA), in its 2023 reassessment, set a UL of 1,000 μg/day for total supplemental folate in adults — explicitly including authorized 5-MTHF salts (calcium-L-methylfolate and glucosamine salt of 5-MTHF) within that combined limit.⁴⁷ Clinicians should therefore be aware that the regulatory treatment of 5-MTHF differs by jurisdiction: in the U.S., no formal UL applies to 5-MTHF (though caution at high doses is warranted); in the EU, 5-MTHF falls under the combined supplemental folate UL. High-dose clinical use of l-methylfolate (e.g., 7.5–15 mg for depression) exceeds both thresholds and proceeds under clinical judgment rather than dietary guideline compliance.

Adverse effects and considerations by form:

• Folic acid: Masking of B¹² deficiency (hematologic correction without neurologic protection); theoretical concerns about UMFA and cancer promotion at very high intakes; possible immune modulation at high doses.
• 5-MTHF: Clinical symptoms sometimes described as 'overmethylation' (anxiety, irritability, insomnia, headache) in sensitive individuals. Dose titration is advisable. May lower seizure threshold at very high doses in susceptible individuals — a theoretical concern with limited documentation.
• Folinic acid: Generally well tolerated at therapeutic doses. In neuropsychiatric use, initial behavioral activation or irritability may occur and typically resolves with dose adjustment.

9. Special Populations

9.1 Pediatrics

Folate requirements are proportionally higher in children relative to body weight due to rapid growth and cell division. Recommended Dietary Allowances range from 65 μg DFE in infancy to 400 μg DFE by age 14. The use of folinic acid in autism spectrum disorder (discussed in Section 6.4) represents a growing area of pediatric integrative practice.⁴⁸

9.2 Geriatrics

Older adults are at increased risk of folate deficiency due to reduced dietary intake, malabsorption, and concurrent B¹² deficiency. The VITACOG trial showed that B-vitamin supplementation (including folic acid) slowed brain atrophy in older adults with elevated homocysteine and mild cognitive impairment.⁴⁹

9.3 Pregnancy and Lactation

The RDA for folate during pregnancy is 600 μg DFE/day. Most prenatal supplements provide 800–1000 μg of folic acid or equivalent. Folate is preferentially partitioned to breast milk, so maternal deficiency can develop before infant deficiency becomes apparent.⁵⁰

10. Dietary Sources and Food Fortification

Rich natural food sources of folate include dark leafy greens (spinach, kale, collards), legumes (lentils, chickpeas, black beans), asparagus, Brussels sprouts, broccoli, beets, avocado, citrus fruits, and liver. Food folates are heat-labile and water-soluble, with cooking losses of 50–95% depending on method and duration.

Since 1998, the United States has mandated fortification of enriched cereal grain products with folic acid at 140 μg per 100 g of grain.⁵¹ Globally, Garrett and Bailey reported that 81 countries mandate fortification of wheat flour, maize flour, or rice with folic acid specifically, and a larger number mandate fortification of a cereal grain with at least one nutrient; the count has continued to grow since.⁵² The fortification debate continues to evolve, with some countries exploring the use of 5-MTHF as the fortification agent (to avoid UMFA concerns), though regulatory, stability, and cost barriers remain.

11. Emerging Research Directions

The folate field continues to expand in several directions:

• Epigenomics and DOHaD: Periconceptional folate status influences DNA methylation patterns in offspring with potential transgenerational effects, connecting folate to the developmental origins of health and disease (DOHaD) paradigm.
• Microbiome-folate axis: Commensal gut bacteria synthesize folate de novo, contributing to host folate status. The interaction between dietary folate, supplemental forms, and microbial folate production is an emerging area with implications for personalized nutrition.⁵³
• Folate receptor-targeted therapies: FRα overexpression in ovarian, lung, and breast cancers has spawned a class of folate-conjugated drug delivery systems and antibody-drug conjugates (e.g., mirvetuximab soravtansine) that exploit folate receptors for targeted cancer therapy.
• Precision nutrition: Integration of MTHFR genotyping, UMFA measurement, homocysteine dynamics, and FRα autoantibody status into a comprehensive folate metabolism assessment panel for personalized supplementation.
• Mast cell activation and folate: Preliminary clinical observations in mast cell activation syndrome (MCAS) populations suggest that some patients exhibit differential tolerance of folate forms — for example, reported intolerance of folic acid with better tolerance of folinic acid or 5-MTHF. However, no controlled studies have evaluated this association, and the mechanism (if real) remains entirely speculative. This observation should be considered hypothesis-generating only.
• Mitochondrial folate metabolism: The mitochondrial folate cycle (involving MTHFD2, SHMT2, and related enzymes) plays a critical role in one-carbon metabolism within mitochondria, supporting formate production for cytoplasmic one-carbon reactions. Dysregulation is implicated in cancer metabolism and is a target for emerging therapeutic strategies.⁵⁴

12. Clinical Decision Framework

Synthesizing the evidence, a practical clinical decision framework for folate form selection can be organized as follows:

• Step 1 — Assess indication: General wellness, prenatal care, NTD prevention, methotrexate management, neuropsychiatric condition, or cancer context?
• Step 2 — Evaluate genetic status: MTHFR genotype (if available), family history of NTDs, history of elevated homocysteine, or pharmacogenomic panel results.
• Step 3 — Review concurrent medications: Methotrexate (high-dose or low-dose?), anticonvulsants, metformin, PPIs, or other folate-depleting agents.
• Step 4 — Assess CNS considerations: Suspicion for cerebral folate deficiency, FRα autoantibodies, treatment-resistant depression, or autism spectrum presentations.
• Step 5 — Select form and dose: Match the folate form to the clinical scenario. Consider cofactor optimization (B¹², B⁶, B², choline, betaine). Monitor response with appropriate laboratory parameters.
• Step 6 — Reassess and adjust: Monitor homocysteine, RBC folate, clinical response, and side effects. Be attentive to overmethylation symptoms with 5-MTHF and dose-adjust accordingly.

13. Conclusion

The folate story is no longer a single-nutrient, one-size-fits-all narrative. What began with Lucy Wills and a yeast extract has evolved into a nuanced clinical landscape where the form of supplementation matters as much as the dose — where genetic variability, drug interactions, disease context, and even the patient's methylation phenotype all inform the optimal strategy. Folic acid, 5-MTHF, and folinic acid are not interchangeable; they occupy distinct biochemical niches and serve different clinical purposes.

For the clinician practicing at the intersection of evidence-based and integrative medicine, competence in folate biochemistry is not optional — it is foundational. This chapter has attempted to provide that foundation in sufficient depth to support confident, individualized clinical decision-making while remaining grounded in the published evidence base.

As the field moves toward precision nutrition and pharmacogenomics-guided supplementation, the distinctions outlined here will only become more clinically relevant. The practitioner who understands not only what to prescribe but why — and who can articulate the mechanistic rationale to patients and colleagues alike — is uniquely positioned to optimize outcomes in this critical area of human metabolism.

14. Summary and Key Points

The following points distill the chapter into the conclusions most likely to change clinical practice. Each is supported in the sections above; readers are directed there for the underlying evidence and its limitations.

14.1 Biochemistry

• The three forms differ by oxidation state and by where they enter one-carbon metabolism. Folic acid is fully oxidized and biologically inert until reduced; food folates and 5-MTHF are already reduced; folinic acid enters downstream of dihydrofolate reductase entirely.
• Human dihydrofolate reductase activity is low and highly variable, which is why folic acid intake above roughly 200–400 μg in a single dose can produce unmetabolized folic acid in the circulation.
• 5-Methyltetrahydrofolate, not folic acid, is the body’s principal circulating folate, accounting for more than 90% of serum folate under normal conditions.
• Folate metabolism is inseparable from the methionine cycle. Impaired folate handling propagates into SAMe production, DNA and histone methylation, neurotransmitter metabolism, and nucleotide synthesis.

14.2 Pharmacogenomics

• MTHFR C677T reduces enzyme activity to roughly 30% (TT) or 65% (CT) of wild type, but clinical significance is modulated by folate status — adequate intake can largely normalize homocysteine even in TT carriers.
• MTHFR genotype is a susceptibility factor, not a diagnosis. Routine testing in asymptomatic individuals is not endorsed by current guidance, and the genotype should never be treated as a stand-alone disease entity.
• Variants beyond MTHFR — in DHFR, MTR, MTRR, FOLR1, SLC19A1, SLC46A1, TYMS, and CBS — also shape folate handling. FOLR1 mutations cause cerebral folate transport deficiency; SLC46A1 mutations cause hereditary folate malabsorption. These are distinct disorders and should not be conflated.

14.3 Form Selection

• Folic acid remains appropriate for population fortification and for patients without polymorphisms, unmetabolized folic acid concerns, or neuropsychiatric indications. It carries by far the strongest population-level outcome evidence, particularly for neural tube defect prevention.
• 5-MTHF bypasses both the DHFR and MTHFR bottlenecks and generates no unmetabolized folic acid. It is reasonable in documented MTHFR variants with functional impairment, elevated homocysteine, depression augmentation, and higher-risk pregnancies — while acknowledging that comparative outcome data against folic acid for neural tube defect prevention do not yet exist.
• Folinic acid is the appropriate choice for methotrexate rescue, cerebral folate deficiency, and neuropsychiatric presentations where central nervous system folate delivery is in question, including autism spectrum disorder with folate receptor alpha autoantibodies. In cerebral folate deficiency, folic acid may worsen the picture by occupying residual receptors without delivering active folate centrally.

14.4 Clinical Practice

• Folate does not act alone. Vitamin B12 deficiency can create a methyl trap in which 5-MTHF accumulates but cannot donate its methyl group; riboflavin, vitamin B6, betaine, and choline all support one-carbon flux.
• Screen for folate-depleting medications: methotrexate, trimethoprim, pyrimethamine, anticonvulsants, sulfasalazine, and metformin among them.
• Assess with RBC folate for longer-term status, homocysteine as a functional marker, and methylmalonic acid to separate B12 from folate deficiency. Reserve folate receptor alpha autoantibody testing for suspected cerebral folate deficiency and treatment-resistant neuropsychiatric presentations.
• Upper limits differ by jurisdiction. The U.S. limit of 1,000 μg/day applies to synthetic folic acid; the European assessment includes authorized 5-MTHF salts within a combined supplemental folate limit. High-dose therapeutic l-methylfolate exceeds both and proceeds on clinical judgment.

14.5 Where the Evidence Is Thin

Intellectual honesty about the limits of the evidence is part of practicing well in this area. Three claims commonly asserted with more confidence than the literature supports:

• The clinical harm of unmetabolized folic acid remains a mechanistic concern with incomplete outcome data. Public health authorities continue to endorse fortification on the strength of the neural tube defect evidence.
• Superiority of 5-MTHF over folic acid for neural tube defect prevention is supported by pharmacokinetic reasoning, not by comparative outcome trials.
• Overmethylation as a response to methylfolate is a clinical construct reported anecdotally. No published study has demonstrated it directly or shown that COMT genotype predicts susceptibility. Conservative dose titration is a precaution, not an evidence-based protocol.

References

1. Wills L. Treatment of 'pernicious anaemia of pregnancy' and 'tropical anaemia' with special reference to yeast extract as a curative agent. BMJ. 1931;1(3676):1059–1064.

2. Mitchell HK, Snell EE, Williams RJ. The concentration of 'folic acid.' J Am Chem Soc. 1941;63(8):2284.

3. Bleyer WA. The clinical pharmacology of methotrexate: new applications of an old drug. Cancer. 1978;41(1):36–51.

4. Stover PJ. Physiology of folate and vitamin B¹² in health and disease. Nutr Rev. 2004;62(6 Pt 2):S3–S12.

5. Caudill MA. Folate bioavailability: implications for establishing dietary recommendations and optimizing status. Am J Clin Nutr. 2010;91(5):1455S–1460S.

6. Bailey LB, Stover PJ, McNulty H, et al. Biomarkers of nutrition for development — folate review. J Nutr. 2015;145(7):1636S–1680S.

7. Priest DG, Schmitz JC, Bunni MA, Stuart RK. Pharmacokinetics of leucovorin metabolites in human plasma as a function of dose administered orally and intravenously. J Natl Cancer Inst. 1991;83(24):1806–1812.

8. Zhao R, Matherly LH, Goldman ID. Membrane transporters and folate homeostasis: intestinal absorption and transport into systemic compartments and tissues. Expert Rev Mol Med. 2009;11:e4.

9. Grapp M, Wrede A, Schweizer M, et al. Choroid plexus transcytosis and exosome shuttling deliver folate into brain parenchyma. Nat Commun. 2013;4:2123.

10. Bailey SW, Ayling JE. The extremely slow and variable activity of dihydrofolate reductase in human liver and its implications for high folic acid intake. Proc Natl Acad Sci U S A. 2009;106(36):15424–15429.

11. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10(1):111–113.

12. Finkelstein JD. Methionine metabolism in mammals. J Nutr Biochem. 1990;1(5):228–237.

13. Blount BC, Mack MM, Wehr CM, et al. Folate deficiency causes uracil misincorporation into human DNA and chromosome breakage: implications for cancer and neuronal damage. Proc Natl Acad Sci U S A. 1997;94(7):3290–3295.

14. Stover PJ, Field MS. Trafficking of intracellular folates. Adv Nutr. 2011;2(4):325–331.

15. Kelly P, McPartlin J, Goggins M, Weir DG, Scott JM. Unmetabolized folic acid in serum: acute studies in subjects consuming fortified food and supplements. Am J Clin Nutr. 1997;65(6):1790–1795.

16. Willems FF, Boers GHJ, Blom HJ, Aengevaeren WRM, Verheugt FWA. Pharmacokinetic study on the utilisation of 5-methyltetrahydrofolate and folic acid in patients with coronary artery disease. Br J Pharmacol. 2004;141(5):825–830.

17. Obeid R, Kasoha M, Kirsch SH, Munz W, Herrmann W. Concentrations of unmetabolized folic acid and primary folate forms in pregnant women at delivery and in umbilical cord blood. Am J Clin Nutr. 2010;92(6):1416–1422.

18. Schilsky RL, Ratain MJ. Clinical pharmacokinetics of high-dose leucovorin calcium after intravenous and oral administration. J Natl Cancer Inst. 1990;82(17):1411–1415.

19. Smith AD, Kim Y-I, Refsum H. Is folic acid good for everyone? Am J Clin Nutr. 2008;87(3):517–533.

20. Wilcken B, Bamforth F, Li Z, et al. Geographical and ethnic variation of the 677C>T allele of 5,10 methylenetetrahydrofolate reductase (MTHFR): findings from over 7000 newborns from 16 areas worldwide. J Med Genet. 2003;40(8):619–625.

21. Long S, Goldblatt J. MTHFR genetic testing: controversy and clinical implications. Aust Fam Physician. 2016;45(4):237–240.

22. Kalmbach RD, Choumenkovitch SF, Troen AP, et al. A 19-base pair deletion polymorphism in dihydrofolate reductase is associated with increased unmetabolized folic acid in plasma and decreased red blood cell folate. J Nutr. 2008;138(12):2323–2327.

23. Steinfeld R, Grapp M, Kraetzner R, et al. Folate receptor alpha defect causes cerebral folate transport deficiency: a treatable neurodegenerative disorder associated with disturbed myelin metabolism. Am J Hum Genet. 2009;85(3):354–363.

24. Kraus JP, Janosík M, Kozich V, et al. Cystathionine beta-synthase mutations in homocystinuria. Hum Mutat. 1999;13(5):362–375.

25. MRC Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet. 1991;338(8760):131–137.

26. Prinz-Langenohl R, Brämswig S, Tobolski O, et al. [6S]-5-methyltetrahydrofolate increases plasma folate more effectively than folic acid in women with the homozygous or wild-type 677C→T polymorphism of methylenetetrahydrofolate reductase. Br J Pharmacol. 2009;158(8):2014–2021.

27. Martí-Carvajal AJ, Solà I, Lathyris D, Dayer M. Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev. 2017;8(8):CD006612.

28. Huo Y, Li J, Qin X, et al. Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial. JAMA. 2015;313(13):1325–1335.

29. Kim Y-I. Folate and colorectal cancer: an evidence-based critical review. Mol Nutr Food Res. 2007;51(3):267–292.

30. Howard SC, McCormick J, Pui C-H, Buddington RK, Harvey RD. Preventing and managing toxicities of high-dose methotrexate. Oncologist. 2016;21(12):1471–1482.

31. Thirion P, Michiels S, Pignon JP, et al. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol. 2004;22(18):3766–3775.

32. Ramaekers VT, Blau N. Cerebral folate deficiency. Dev Med Child Neurol. 2004;46(12):843–851.

33. Ramaekers VT, Rothenberg SP, Sequeira JM, et al. Autoantibodies to folate receptors in the cerebral folate deficiency syndrome. N Engl J Med. 2005;352(19):1985–1991.

34. Frye RE, Slattery J, Delhey L, et al. Folinic acid improves verbal communication in children with autism and language impairment: a randomized double-blind placebo-controlled trial. Mol Psychiatry. 2018;23(2):247–256.

35. Coppen A, Bolander-Gouaille C. Treatment of depression: time to consider folic acid and vitamin B¹². J Psychopharmacol. 2005;19(1):59–65.

36. U.S. Food and Drug Administration. Guidance for Industry: Frequently Asked Questions About Medical Foods; Third Edition. Silver Spring, MD: FDA; March 2023. [Deplin® is marketed as a medical food under 21 USC §360ee and 21 CFR 101.9; it is not FDA-approved as a drug.]

37. Papakostas GI, Shelton RC, Zajecka JM, et al. L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials. Am J Psychiatry. 2012;169(12):1267–1274.

38. Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL, Weinshilboum RM. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics. 1996;6(3):243–250.

39. Hodgetts VA, Morris RK, Francis A, Gardosi J, Ismail KM. Effectiveness of folic acid supplementation in pregnancy on reducing the risk of small-for-gestational age neonates: a population study, systematic review and meta-analysis. BJOG. 2015;122(4):478–490.

40. Liu C, Liu C, Wang Q, Zhang Z. Supplementation of folic acid in pregnancy and the risk of preeclampsia and gestational hypertension: a meta-analysis. Arch Gynecol Obstet. 2018;298(4):697–704.

41. van Beynum IM, Kapusta L, Bakker MK, den Heijer M, Blom HJ, de Walle HEK. Protective effect of periconceptional folic acid supplements on the risk of congenital heart defects: a registry-based case–control study in the northern Netherlands. Eur Heart J. 2010;31(4):464–471.

42. Surén P, Roth C, Bresnahan M, et al. Association between maternal use of folic acid supplements and risk of autism spectrum disorders in children. JAMA. 2013;309(6):570–577.

43. Jamison RL, Hartigan P, Kaufman JS, et al. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. JAMA. 2007;298(10):1163–1170.

44. Whittle SL, Hughes RA. Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review. Rheumatology (Oxford). 2004;43(3):267–271.

45. McNulty H, Dowey LRC, Strain JJ, et al. Riboflavin lowers homocysteine in individuals homozygous for the MTHFR 677C→T polymorphism. Circulation. 2006;113(1):74–80.

46. Institute of Medicine. Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline. Washington, DC: National Academies Press; 1998.

47. EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA). Scientific opinion on the tolerable upper intake level for folate. EFSA J. 2023;21(11):8353. doi:10.2903/j.efsa.2023.8353

48. Bailey LB, Gregory JF III. Folate metabolism and requirements. J Nutr. 1999;129(4):779–782.

49. Smith AD, Smith SM, de Jager CA, et al. Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. PLoS One. 2010;5(9):e12244.

50. Tamura T, Picciano MF. Folate and human reproduction. Am J Clin Nutr. 2006;83(5):993–1016.

51. Choumenkovitch SF, Selhub J, Wilson PWF, Rader JI, Rosenberg IH, Jacques PF. Folic acid intake from fortification in United States exceeds predictions. J Nutr. 2002;132(9):2792–2798.

52. Garrett GS, Bailey LB. A public health approach for preventing neural tube defects: folic acid fortification and beyond. Ann N Y Acad Sci. 2018;1414(1):47–58.

53. Engevik MA, Morra CN, Röth D, et al. Microbial metabolic capacity for intestinal folate production and modulation of host folate receptors. Front Microbiol. 2019;10:2305.

54. Ducker GS, Rabinowitz JD. One-carbon metabolism in health and disease. Cell Metab. 2017;25(1):27–42.